Last reviewed · How we verify
Aggressive medical treatment
At a glance
| Generic name | Aggressive medical treatment |
|---|---|
| Also known as | Dual antiplatelet therapy for 6 months |
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hives
- Throat Tightness
- Hypotension
- Elevation in Fever
- Tachycardia
- Tachypnea
- Hypertension
- Confusion
- Seizure
- Difficulty Breathing
- Chills
- Vomiting
Key clinical trials
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas (PHASE3)
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (PHASE2)
- Evolution of Empathy and Emotional Intelligence During a Doctor-patient Relationship Training
- Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- Remote Training in Rural Schools (NA)
- Death, Dying, Violence and Aggression as Shown on Medical Television Series.
- Sustainment of Mental Health Supports (NA)
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aggressive medical treatment CI brief — competitive landscape report
- Aggressive medical treatment updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI